{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:17:36Z","timestamp":1787887056846,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejso.2025.111374","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T22:56:35Z","timestamp":1766876195000},"page":"111374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Understanding divergent outcomes: A comparative analysis of ESOPEC and CROSS real-world studies in esophageal adenocarcinoma"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3925-6871","authenticated-orcid":false,"given":"Pascal","family":"Burri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3161-5822","authenticated-orcid":false,"given":"Stavros","family":"Chatziisaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chatziisaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.111374_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1440-1746.2009.05824.x","article-title":"Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity","volume":"24","author":"Hongo","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2025.111374_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers13010141","article-title":"Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2025.111374_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2025.111374_bib4","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejso.2025.111374_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2025.111374_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2025.111374_bib7","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.111374_bib8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.111374_bib9","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT versus FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2\u2013Positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111374_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103067","article-title":"Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands","volume":"80","author":"van Laarhoven","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejso.2025.111374_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000531536","article-title":"Real-world outcomes of FLOT versus CROSS regimens for patients with oesophagogastric cancers","volume":"10","author":"Shahnam","year":"2023","journal-title":"Gastrointest Tumors"},{"key":"10.1016\/j.ejso.2025.111374_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111374_bib13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2025.111374_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2025.111374_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejso.2025.111374_bib16","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111374_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7076","article-title":"Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis","volume":"13","author":"Gaber","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejso.2025.111374_bib18","article-title":"A comprehensive narrative review on paradigm shift in the treatment of esophageal and rectal cancer","volume":"4","author":"Chatziisaak","year":"2025","journal-title":"Clin Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111374_bib19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/SLA.0000000000003636","article-title":"Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study","volume":"274","author":"van der Wilk","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111374_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae036","article-title":"Active surveillance for clinical complete responders after chemoradiotherapy for oesophageal squamous cell carcinoma","volume":"111","author":"De Pasqual","year":"2024","journal-title":"BJS"},{"key":"10.1016\/j.ejso.2025.111374_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bjc.2012.588","article-title":"Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer","volume":"108","author":"Lorenzen","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2025.111374_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102072","article-title":"Dose reduced preoperative chemotherapy in older patients with resectable gastroesophageal cancer: a real-world data study","volume":"15","author":"Skjoldbirk","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.ejso.2025.111374_bib23","doi-asserted-by":"crossref","first-page":"TPS431","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS431","volume":"42","author":"Goetze","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325018025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325018025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:28:58Z","timestamp":1783736938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325018025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0748798325018025"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111374","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding divergent outcomes: A comparative analysis of ESOPEC and CROSS real-world studies in esophageal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111374"}}